P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity - Université de Bourgogne Accéder directement au contenu
Article Dans Une Revue QJM: An International Journal of Medicine Année : 2016

P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity

Résumé

Bleomycin is an anti-cancer drug used to treat different malignancies, mainly lymphomas, germ cell tumors. Unfortunately, bleomycin has major, pulmonary toxicity that affects 20% of treated individuals with pulmonary fibrosis being the most devastating form. Deglyco-bleomycin is a molecule derived from bleomycin in which the sugar residue D-mannosyl-L-glucose disaccharide has been deleted. The objective of this study is to assess the anti-cancerous activity and the lung toxicity of deglyco-bleomycin. We compared in vivo the antitumor activity in three rodent models after intraperitoneal administrated deglyco-bleomycin and bleomycin. Pulmonary toxicity was in depth examined after intratracheal administration of both chemotherapeutic agents. We demonstrate in vivo in rodent cancer models, including a human Hodgkin lymphoma xenograft and a syngeneic melanoma model, that intra-peritoneal deglyco-bleomycin is as effective as bleomycin...

Dates et versions

hal-01512940 , version 1 (24-04-2017)

Identifiants

Citer

Olivier Burgy, Guillaume Wettstein, Pierre-Simon Bellaye Bellaye, Nathalie Decologne, Cindy Racoeur, et al.. P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity. QJM: An International Journal of Medicine, 2016, 109 (suppl_1), pp.S58. ⟨10.1093/qjmed/hcw120.006⟩. ⟨hal-01512940⟩
113 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More